Rapport Therapeutics, Inc. Common Stock
Financials
Valuation Metrics
Rapport Therapeutics, Inc. Common Stock's Market Cap is $1.93B. At end of 2025 it was $1.43B. Ranked #2033 of 3,121 in US market (top 65%), #779 of 1,463 on NASDAQ (top 53%), #140 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.93B | US#2,033/3,121 Sec#140/266 |
| Revenue | $20M | US#2,820/3,121 Sec#165/266 |
| Net Income | $-137M | US—/3,121 Sec—/266 |
| Total Assets | $459M | US#2,806/3,121 Sec#175/266 |
| Net Assets | $423M | US#2,342/3,121 Sec#128/266 |
| Employees | 84 | US#2,660/3,121 Sec#190/266 |
| Value | ||
| P/B | 4.57x | US#2,173/3,121 Sec#135/266 |
| P/S | 96.73x | US#2,947/3,121 Sec#177/266 |
| FCF Yield | -5.02% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -32.43% | US#2,585/3,121 Sec#118/266 |
| ROA | -29.88% | US#2,881/3,121 Sec#154/266 |
| Op. Margin | -767.58% | US#2,822/3,121 Sec#163/266 |
| Financial Health | ||
| Debt Ratio | 8.53% | US#87/3,121 Sec#40/266 |
| Total Debt | $10M | US#2,834/3,121 Sec#199/266 |
| FCF | $-97M | US#2,623/3,121 Sec#139/266 |
| Cash | $64M | US#2,469/3,121 Sec#211/266 |
| Current Ratio | 15.72x | US#161/3,121 Sec#47/266 |
| Performance | ||
| 1Y Return | 47.90% | US#460/3,121 Sec#94/266 |
| 1M Return | -17.57% | US#2,778/3,121 Sec#215/266 |
| From 52W High | -23.58% | US#1,553/3,121 Sec#113/266 |
| 1Y MDD | -28.82% | US#1,334/3,121 Sec#84/266 |
| Trading | ||
| Volume | 773,741 shares | US#2,238/3,121 Sec#229/266 |
| Trading Value | $32M | US#2,040/3,121 Sec#159/266 |
| Per Share | ||
| EPS | $-2.87 | US—/3,121 Sec—/266 |
| BPS | $8.84 | US#1,923/3,121 Sec#77/266 |
Company Info
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.